» Upcoming Conference BABE-2015, August 17-19, 2015 Chicago, USA
Upcoming Conference: BABE-2015, August 17-19, 2015 Chicago, USA            
Untitled Document

               
     

    OMICS Group’s
    2nd World Congress on Bioavailability &     Bioequivalence: Pharmaceutical R & D Summit-2011
                                                        and
    International Conference on Pharmaceutics & Novel Drug Delivery Systems

    Theme: Analyze Novel Approaches of  Bioavailability & Bioequivalence Studies and Advancements in Pharmaceutics & Novel Drug Delivery Systems
    Dates : 06-08 June 2011
    Venue: Renaissance, Las Vegas, USA

      Call       Fax  Toll Free
    +1-650-268-9744  +1-650-618-1414 +1-800-216-6499


    Website:

    https://www.omicsonline.org/BABE2011/ & https://www.omicsonline.org/pharmaceutica2011/

    Submit Your Abstract Online at:

    https://www.omicsonline.org/BABE2011/abstract.php

    https://www.omicsonline.org/pharmaceutica2011/abstracts.php

    (or) E-mail to:

    babe2011@omicsonline.org, BABE2011@omicsonline.biz & pharmaceutica2011@omicsonline.org

    We warmly invite you to attend and submit your abstract to 2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems.


    BABE-2011 & Pharmaceutica-2011 is comprised of 17 tracks and 71 sessions designed to offer comprehensive sessions that address current issues in Pharmaceutics & Novel Drug Delivery Systems,
    Bioavailability & Bioequivalence research.

    Please submit your abstract to any of the following track.
    Track 1: Drug Design, Discovery and Development
    Track 1-1:Drug Design, Development and Therapy
    Track 1-2:New Strategies for Drug Development
    Track 1-3:Epidemiology of Drug Interactions: Biochemical Mechanisms of Drug Toxicity
    Track 1-4:Integrated Product Development: Structure Based Drug Design
    Track 1-5:CNS Drug Development: Principles, Transport Kinetics, Diseases & Methods
    Track 2: Identification and Characterization of Drugs
    Track 2-1:Characterization of Synthetic and Natural Products
    Track 2-2:Structural Analysis: Characterization of Process or Product Related Impurities and Degradants
    Track 2-3:Instrumental Methods for Identification and Characterization
    Track 2-4:Metabolite Characterization: Drug Discovery
    Track 2-5:Advanced Techniques in Structure Characterization
    Track 3: Bioanalytical Methodology Development and Validation Using HPLC and LCMS
    Track 3-1:Advances in Mass Spectrometry Methodology Development and Pharmaceutical Applications
    Track 3-2:Evaluation of Bioequivalence of Highly Variable Drugs and Drug Products
    Track 3-3:Design and Evaluation of BE Studies and Biosensing
    Track 3-4:Validation of a Sensitive LC-MS/MS Assay to Quantify the Biomarkers
    Track 4: PK/PD and Drug Discovery
    Track 4-1:Anticancer, Antiviral, Antibacterial & Antifungal Drug Development
    Track 4-2:Molecular Drug Target and Fragment Based Drug Design   
    Track 4-3:Improving ADME/DMPK Profile
    Track 4-4:PK/PD and Bioanalysis Outsourcing Alliance
    Track 4-5:Road Map to Drug Discovery and Development
    Track 4-6:New Perspective in Anti-Infective Drugs PK/PD
    Track 5: PK/PD Models, Biowaivers and Biosimilars
    Track 5-1:Biosimilars and Biowavers in BA/BE studies
    Track 5-2:Innovation in Bioanalysis: Drug Discovery to Drug Development
    Track 5-3:Chiral Method for Bioanalysis
    Track 5-4:Pharmacokinetics/Physicochemistry Perspective
    Track 6: Pharmacokinetics, Bioavailability and Bioequivalence
    Track 6-1:Pharmacokinetic Concepts in Drug Development
    Track 6-2:Harmonization of BA/BE studies: Regulatory Aspects
    Track 6-3:BA/BE studies of Pharmacokinetic Drug Interactions
    Track 6-4:Role of Clinical Pharmacology Department in Conducting BA/BE studies:Safety
                   Reporting Requirements
    Track 6-5:BA/BE: Diabetis & Vascular Diseases
    Track 7: Strategies and Challenges in Bioanalysis
    Track 7-1:Stability Issues in Bioanalytical Method Development
    Track 7-2:Bioanalytical Method Development and Validation for Quantitation
    Track 7-3:Advancement in Quantitative Bioanalysis by LC-MS: Metabolite Quantitation
    Track 7-4:Method Development Strategies to Increase Sensitivity of Analytical Instruments
    Track 7-5:Biomedicine Pharmacotherapy
    Track 8: Biopharmaceuticals Development
    Track 8-1:Biopharmaceutics and Formulation Development
    Track 8-2:Role of PK/PD in Product Development
    Track 8-3:Drug Development of Pediatrics: Formulation and Regulatory Aspects
    Track 8-4:Bioavailability and Bioequivalence in Disease State
    Track 8-5:Applied Pharmacokinetics and Pharmacodynamics
    Track 9: Practical Solutions to Pharmaceutical BA/BE Implementation
    Track 9-1:Bioequivalence Strategies in Development – an Industry Perspective
    Track 9-2:Comparative Bioavailability Studies for New Drugs (NDA)
    Track 9-3:Comparative Bioavailability Generic Drug products (ANDA): Bioequivalence Studies
    Track 9-4:Quality Management System for BA/BE Studies
    Track 10: Considerations for Conducting BA/BE Studies
    Track 10-1:Design, Documentation and Reporting of BA/BE Studies: Protocol Issues
    Track 10-2:Characteristics Investigated during Bioavailability and Bioequivalence Study
    Track 10-3:Statistical Considerations for BA/BE Studies
    Track 10-4:Bioanalytical Compliances for BA/BE Study
    Track 10-5:Bioanalytical Methods: Clinical Pharmacology
    Track 11: Regulatory and Economical Aspects in BA/BE
    Track 11-1:Global Generic Market: Overview
    Track 11-2:Regulatory Aspects of Conduct in BA/BE Studies for Treatments in Special Populations
    Track 11-3:Regulated Bioanalysis: Updates from Regulatory Agencies
    Track 11-4:Safety Monitoring Boards and Ethical Committees for BA/BE Studies
    Track 12: Novel Drug Delivery Systems
    Track 12-1:Targeted Drug Delivery Systems
    Track 12-2:Parenteral Sustained Release Drug Delivery Systems
    Track 12-3:Advanced Drug Delivery Systems:Occular,Inhalationand Transdermal Drug Delivery
                    Systems
    Track 12-4:Formulation and Characterization of Novel Drug Delivery Systems
    Track 12-5:Controlled Drug Delivery Systems by Using Nanotechnology
    Track 13: BA/BE of Novel Drug Delivery Systems
    Track 13.1:Sustained Release Dosage Forms
    Track 13.2:Targeted Drug Delivery Systems
    Track 13.3:Transdermal Drug Delivery Systems
    Track 13.4:Pulmonary Drug Delivery Systems
    Track 13.5:Topical Dermatological Drug Products
    Track 14: Quality Management System in Pharmaceutical Industry
    Track 14.1:Pharmaceutical Development and Quality System
    Track 14.2:Quality Assurance and Quality Control for Pharmaceutical Development
    Track 14.3:Pharmacovigilance and Safety management
    Track 14.4:Quality Assessment for Pharmaceutical Products
    Track 14.5:Food and Drug Safety
    Track 14.6:Regulatory and Economical Aspects of Pharmaceutical Formulations
    Track 15: Clinical Investigations
    Track 15.1:Clinical Trials and Post-Marketing Surveillance
    Track 15.2:Advancements in Clinical Investigations
    Track 15.3:Clinical Trials in Pediatrics
    Track 15.4:Preclinical and Clinical Development of Pharmaceutical Products
    Participants List
    Academia
    Untitled Document
    University of Texas at Arlington, USA

    Stanford University School of Medicine, USA

    Mahidol University, Thailand

    Amirkabir University of Technology, Iran

    Hamdard University, India

    Yeshiva University, USA

    University of Macau, China

    Monash University, Australia

    University of Michigan, Ann Arbor

    Universidade Federal do Rio de Janeiro, Brazil

    University of Denver, Colorado

    University of Toronto, Canada

    Zagazig University, Egypt

    Banaras Hindu University, India

    Taipei Medical University, Taiwan

    Università di Messina CNISM, Italy

    University of Tasmania, Australia

    Huazhong University of Science and Technology, China

    Sogang University, Korea

    University of Edinburgh, UK

    Martin-Luther-Universität Halle-Wittenberg, Halle/Saale

    Universidade de São Paulo, Brazil

    Eve University, Turkey

    University of Delhi, India

    Isfahan University of Technology(IUT), Iran

    Taif University, Saudi Arabia

    University Medical Center, Netherlands

    University of Copenhagen, Denmark

    Université Paris 13, France
    Business
    Untitled Document
    Cadila Pharmaceuticals, India

    Chemical Works of Gedeon Richter, Hungary

    3S-Pharmacological Consultation & Research GmbH, Germany

    Royal Brisbane and Women’s Hospital, Australia

    Psoriasis and Cutaneous Inflammation Research Laboratory, USA

    Alcon Laboratories Inc., USA

    National Institute for Materials Science (NIMS), Japan

    Grup de Recerca de Reumatologia (IRHVH), Spain

    Bayer Health Care, Richmond, USA

    Crown Bioscience Inc., China

    Hammersmith Hospital, London

    Van Drie Research LLC, USA

    Dr.Reddy’s labs, India

    Merck Research Laboratories, USA

    National Institute of Pharmaceutical Education and Research (NIPER), India

    AstraZeneca R&D Boston, USA

    Abbott Laboratories, USA

    Hutchison MediPharma Limited, China

    Sage Bionetworks, USA

    Central Drug Research Institute, India

    Glenmark Pharmaceuticals, India

    National Institute for Interdisciplinary Science & Technology (NIIST) , India

    Novartis Campus, Austria



    Operated By: Editors-Journal of Bioequivalence & Bioavailability, Journal of Bioanalysis & Biomedicine and Pharmaceutica Analytica Acta

    Hosting Organization: OMICS Publishing Group